Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities
The approval for the drug, which will be sold under the brand name Foundayo, marks an important technological inflection point for this class of drugs that is transforming obesity care in the US and around the world
This effect is particularly promising for those with type 2 diabetes, as obesity often complicates the management of the condition
Zepbound and Mounjaro use the same active ingredient tirzepatide, similar to semaglutide, FDA-approved for people with obesity or overweight accompanied by diet and fitness
Researchers believe the bodys hunger and reward centers become more active again once the medication leaves the system
Wegovy is a prescription injection used for weight loss, to lower risk of cardiovascular problems, and to treat metabolic dysfunction-associated steatohepatitis (MASH)
US$ 27.63
US$ 21.95
US$ 25.17
US$ 21.12
US$ 22.96
US$ 22.08
US$ 22.55
US$ 21.92
US$ 26.56
US$ 24.85
